Skip to main content
Erschienen in: Clinical and Translational Oncology 10/2014

01.10.2014 | Research Article

High Sam68 expression predicts poor prognosis in non-small cell lung cancer

verfasst von: Z. Zhang, Y. Xu, N. Sun, M. Zhang, J. Xie, Z. Jiang

Erschienen in: Clinical and Translational Oncology | Ausgabe 10/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

The nuclear protein Sam68 has been implicated in the oncogenesis and tumor growth. The aim of this study was to explore the clinical value of Sam68 in patients with non-small cell lung cancer (NSCLC).

Methods

We examined Sam68 expression in 50 NSCLC tissues and matched adjacent noncancerous tissues by quantitative RT-PCR (qRT-PCR) and Western blotting. Furthermore, the Sam68 protein expression was analyzed by immunohistochemistry in 208 NSCLC samples. Kaplan–Meier method and multivariate Cox regression model were used to evaluate the prognostic value of nuclear Sam68 expression in NSCLC for disease survival.

Results

The expression of Sam68 was significantly elevated in NSCLC tissues as compared with adjacent non-cancerous tissues (P < 0.01). The high expression of Sam68 in NSCLC was significantly correlated with lymph node metastasis and tumor TNM stage. Kaplan–Meier survival analysis revealed that high expression of Sam68 correlated with poor prognosis of NSCLC patients (P < 0.01). Multivariate analysis showed that Sam68 expression was an independent prognostic marker for overall survival of NSCLC patients (HR 2.73, 95 % CI 1.549–4.315, P = 0.002).

Conclusion

Our results suggest that high Sam68 expression predicts poor prognosis of NSCLC patients, and Sam68 may be potentially a prognostic biomarker for NSCLC.
Literatur
2.
Zurück zum Zitat Tsim S, O’Dowd CA, Milroy R, Davidson S. Staging of non-small cell lung cancer (NSCLC): a review. Respir Med. 2010;104:1767–74.PubMedCrossRef Tsim S, O’Dowd CA, Milroy R, Davidson S. Staging of non-small cell lung cancer (NSCLC): a review. Respir Med. 2010;104:1767–74.PubMedCrossRef
4.
Zurück zum Zitat Stuschke M, Pöttgen C. Chemotherapy: effectiveness of adjuvant chemotherapy for resected NSCLC. Nat Rev Clin Oncol. 2010;7:613–4.PubMedCrossRef Stuschke M, Pöttgen C. Chemotherapy: effectiveness of adjuvant chemotherapy for resected NSCLC. Nat Rev Clin Oncol. 2010;7:613–4.PubMedCrossRef
5.
Zurück zum Zitat Almeida GM, Duarte TL, Farmer PB, Steward WP, Jones GD. Multiple end-point analysis reveals cisplatin damage tolerance to be a chemoresistance mechanism in a NSCLC model: implications for predictive testing. Int J Cancer. 2008;122:1810–9.PubMedCrossRef Almeida GM, Duarte TL, Farmer PB, Steward WP, Jones GD. Multiple end-point analysis reveals cisplatin damage tolerance to be a chemoresistance mechanism in a NSCLC model: implications for predictive testing. Int J Cancer. 2008;122:1810–9.PubMedCrossRef
6.
Zurück zum Zitat Filipits M, Pirker R. Predictive markers in the adjuvant therapy of non-small cell lung cancer. Lung Cancer. 2011;74:355–63.PubMedCrossRef Filipits M, Pirker R. Predictive markers in the adjuvant therapy of non-small cell lung cancer. Lung Cancer. 2011;74:355–63.PubMedCrossRef
7.
Zurück zum Zitat Lukong KE, Richard S. Sam68, the KH domain-containing superSTAR. Biochim Biophys Acta. 2003;13:73–86. Lukong KE, Richard S. Sam68, the KH domain-containing superSTAR. Biochim Biophys Acta. 2003;13:73–86.
8.
Zurück zum Zitat Taylor SJ, Shalloway D. An RNA-binding protein associated with Src through its SH2 and SH3 domains in mitosis. Nature. 1994;368:867–71.PubMedCrossRef Taylor SJ, Shalloway D. An RNA-binding protein associated with Src through its SH2 and SH3 domains in mitosis. Nature. 1994;368:867–71.PubMedCrossRef
9.
Zurück zum Zitat Fumagalli S, Totty NF, Hsuan JJ, Courtneidge SA. A target for Src in mitosis. Nature. 1994;13:871–4.CrossRef Fumagalli S, Totty NF, Hsuan JJ, Courtneidge SA. A target for Src in mitosis. Nature. 1994;13:871–4.CrossRef
10.
Zurück zum Zitat Bielli P, Busa R, Paronetto MP, Sette C. The RNA-binding protein Sam68 is a multifunctional player in human cancer. Endocr Relat Cancer. 2011;13:R91–102.CrossRef Bielli P, Busa R, Paronetto MP, Sette C. The RNA-binding protein Sam68 is a multifunctional player in human cancer. Endocr Relat Cancer. 2011;13:R91–102.CrossRef
11.
Zurück zum Zitat Babic I, Cherry E, Fujita DJ. SUMO modification of Sam68 enhances its ability to repress cyclin D1 expression and inhibits its ability to induce apoptosis. Oncogene. 2006;13:4955–64.CrossRef Babic I, Cherry E, Fujita DJ. SUMO modification of Sam68 enhances its ability to repress cyclin D1 expression and inhibits its ability to induce apoptosis. Oncogene. 2006;13:4955–64.CrossRef
12.
Zurück zum Zitat Busa R, Paronetto MP, Farini D, Pierantozzi E, Botti F, Angelini DF, et al. The RNA-binding protein Sam68 contributes to proliferation and survival of human prostate cancer cells. Oncogene. 2007;13:4372–82.CrossRef Busa R, Paronetto MP, Farini D, Pierantozzi E, Botti F, Angelini DF, et al. The RNA-binding protein Sam68 contributes to proliferation and survival of human prostate cancer cells. Oncogene. 2007;13:4372–82.CrossRef
13.
Zurück zum Zitat Song L, Wang L, Li Y, Xiong H, Wu J, Li J, et al. Sam68 up-regulation correlates with, and its down-regulation inhibits, proliferation and tumourigenicity of breast cancer cells. J Pathol. 2010;13:227–37.CrossRef Song L, Wang L, Li Y, Xiong H, Wu J, Li J, et al. Sam68 up-regulation correlates with, and its down-regulation inhibits, proliferation and tumourigenicity of breast cancer cells. J Pathol. 2010;13:227–37.CrossRef
14.
Zurück zum Zitat Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest. 2009;136:260–71.PubMedCrossRef Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest. 2009;136:260–71.PubMedCrossRef
15.
Zurück zum Zitat Matter N, Herrlich P, Konig H. Signal-dependent regulation of splicing via phosphorylation of Sam68. Nature. 2002;13:691–5.CrossRef Matter N, Herrlich P, Konig H. Signal-dependent regulation of splicing via phosphorylation of Sam68. Nature. 2002;13:691–5.CrossRef
16.
Zurück zum Zitat Paronetto MP, Cappellari M, Busa R, Pedrotti S, Vitali R, Comstock C, et al. Alternative splicing of the cyclin D1 protooncogene is regulated by the RNA-binding protein Sam68. Cancer Res. 2011;70:229–39.CrossRef Paronetto MP, Cappellari M, Busa R, Pedrotti S, Vitali R, Comstock C, et al. Alternative splicing of the cyclin D1 protooncogene is regulated by the RNA-binding protein Sam68. Cancer Res. 2011;70:229–39.CrossRef
17.
Zurück zum Zitat Valacca C, Bonomi S, Buratti E, Pedrotti S, Baralle FE, Sette C, et al. Sam68 regulates EMT through alternative splicing-activated nonsense-mediated mRNA decay of the SF2/ASF proto-oncogene. J Cell Biol. 2010;191:87–99.PubMedCrossRefPubMedCentral Valacca C, Bonomi S, Buratti E, Pedrotti S, Baralle FE, Sette C, et al. Sam68 regulates EMT through alternative splicing-activated nonsense-mediated mRNA decay of the SF2/ASF proto-oncogene. J Cell Biol. 2010;191:87–99.PubMedCrossRefPubMedCentral
18.
Zurück zum Zitat Rajan P, Gaughan L, Dalgliesh C, El-Sherif A, Robson CN, Leung HY, et al. Regulation of gene expression by the RNA-binding protein Sam68 in cancer. Biochem Soc Trans. 2008;36:505–7.PubMedCrossRef Rajan P, Gaughan L, Dalgliesh C, El-Sherif A, Robson CN, Leung HY, et al. Regulation of gene expression by the RNA-binding protein Sam68 in cancer. Biochem Soc Trans. 2008;36:505–7.PubMedCrossRef
19.
Zurück zum Zitat Liu K, Li L, Nisson PE, Gruber C, Jessee J, Cohen SN. Neoplastic transformation and tumorigenesis associated with sam68 protein deficiency in cultured murine fibroblasts. J Biol Chem. 2000;275:40195–201.PubMedCrossRef Liu K, Li L, Nisson PE, Gruber C, Jessee J, Cohen SN. Neoplastic transformation and tumorigenesis associated with sam68 protein deficiency in cultured murine fibroblasts. J Biol Chem. 2000;275:40195–201.PubMedCrossRef
21.
Zurück zum Zitat Richard S, Vogel G, Huot ME, Guo T, Muller WJ, Lukong KE. Sam68 haploinsufficiency delays onset of mammary tumorigenesis and metastasis. Oncogene. 2008;27:548–56.PubMedCrossRef Richard S, Vogel G, Huot ME, Guo T, Muller WJ, Lukong KE. Sam68 haploinsufficiency delays onset of mammary tumorigenesis and metastasis. Oncogene. 2008;27:548–56.PubMedCrossRef
22.
Zurück zum Zitat Li Z, Yu CP, Zhong Y, Liu TJ, Huang QD, Zhao XH, et al. Sam68 expression and cytoplasmic localization is correlated with lymph node metastasis as well as prognosis in patients with early-stage cervical cancer. Ann Oncol. 2012;23:638–46.PubMedCrossRef Li Z, Yu CP, Zhong Y, Liu TJ, Huang QD, Zhao XH, et al. Sam68 expression and cytoplasmic localization is correlated with lymph node metastasis as well as prognosis in patients with early-stage cervical cancer. Ann Oncol. 2012;23:638–46.PubMedCrossRef
23.
Zurück zum Zitat Zhang Z, Li J, Zheng H, Yu C, Chen J, Liu Z, et al. Expression and cytoplasmic localization of SAM68 is a significant and independent prognostic marker for renal cell carcinoma. Cancer Epidemiol Biomark Prev. 2009;18:2685–93.CrossRef Zhang Z, Li J, Zheng H, Yu C, Chen J, Liu Z, et al. Expression and cytoplasmic localization of SAM68 is a significant and independent prognostic marker for renal cell carcinoma. Cancer Epidemiol Biomark Prev. 2009;18:2685–93.CrossRef
24.
Zurück zum Zitat Paronetto MP, Achsel T, Massiello A, Chalfant CE, Sette C. The RNA-binding protein Sam68 modulates the alternative splicing of Bcl-x. J Cell Biol. 2007;13:929–39.CrossRef Paronetto MP, Achsel T, Massiello A, Chalfant CE, Sette C. The RNA-binding protein Sam68 modulates the alternative splicing of Bcl-x. J Cell Biol. 2007;13:929–39.CrossRef
25.
Zurück zum Zitat Chawla G, Lin CH, Han A, Shiue L, Ares M Jr, Black DL. Sam68 regulates a set of alternatively spliced exons during neurogenesis. Mol Cell Biol. 2009;13:201–13.CrossRef Chawla G, Lin CH, Han A, Shiue L, Ares M Jr, Black DL. Sam68 regulates a set of alternatively spliced exons during neurogenesis. Mol Cell Biol. 2009;13:201–13.CrossRef
Metadaten
Titel
High Sam68 expression predicts poor prognosis in non-small cell lung cancer
verfasst von
Z. Zhang
Y. Xu
N. Sun
M. Zhang
J. Xie
Z. Jiang
Publikationsdatum
01.10.2014
Verlag
Springer Milan
Erschienen in
Clinical and Translational Oncology / Ausgabe 10/2014
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-014-1160-3

Weitere Artikel der Ausgabe 10/2014

Clinical and Translational Oncology 10/2014 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.